EANS-EANO guidelines on the extent of resection in gliomas
- PMID: 40973061
- PMCID: PMC12962633
- DOI: 10.1093/neuonc/noaf217
EANS-EANO guidelines on the extent of resection in gliomas
Abstract
Intense efforts are employed to optimize neurosurgical resection of gliomas in different clinical scenarios. However, the level of evidence employed toward personalized treatment decisions is still moderate. Therefore, a joint task force was created by the European Association for Neurosurgical Societies (EANS) and the European Association of Neuro-Oncology (EANO) in order to provide interdisciplinary guidance on the extent of resection (EOR) in glioma surgery. This task force assessed the data on the EOR in gliomas, evaluated the level of evidence, and composed recommendations. The EOR is determined routinely by postoperative magnetic resonance imaging. Since EOR may be associated with survival and may have an impact on epilepsy, neurocognition, quality of life, neurological status, and also on planning of radiation and pharmacotherapy (evidence classes I-IV), recommendations of different levels can be made for the resection of newly diagnosed glioblastomas (level A), recurrent glioblastomas (level C), newly diagnosed (level B) and recurrent (good practice point) IDH mutant gliomas, ependymomas in children (level B) and adults (good practice point) as well as World Health Organization CNS grade 1 tumors (good practice point). We hereby report the outcome of this collaborative effort by the joint task force between EANS and EANO.
Keywords: glioblastoma; glioma; prognosis; resection; surgery; survival.
© The Author(s) 2025. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Conflict of interest statement
R.G.: none, N.F.: none, F.S.: none, P.S.: none, A.S.J.: none, G.M.: honoraria for lectures, consultation, or advisory board participation from Brainlab, Accuray, Servier, Astra-Zeneca, Pfizer, and Novocure. R.R.: none, M.R.: funding for IIT (Novocure), M.P.: honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen, Adastra, Gan & Lee Pharmaceuticals, Janssen, Servier, Miltenyi, Böhringer-Ingelheim, Telix, Medscape, OncLive, Medac, Nerviano Medical Sciences, and ITM Oncologics GmbH. J.F.: honoraria for lectures, consultation, or advisory board participation from Novarits, Seagen, Sanova, and Servier. R.G.: none, C.M.: funding for IIT (Novocure), A.D.: none, M.W.: research grants from Novartis, Quercis, and Versameb, and honoraria for lectures or advisory board participation or consulting from Anheart, Bayer, Curevac, Medac, Neurosense, Novartis, Novocure, Orbus, Pfizer, Philogen, Roche, and Servier, and M.S.: none.
References
-
- Brainin M, Barnes M, Baron JC, et al. ; Guideline Standards Subcommittee of the EFNS Scientific Committee. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces—revised recommendations 2004. Eur J Neurol. 2004;11:577–581. 10.1111/J.1468-1331.2004.00867.X - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
